National Center for Tumor Diseases (NCT) Heidelberg
Marco Rheinnecker is a Bioinformatician at the National Center for Tumor Diseases (NCT) Heidelberg since April 2020. Marco has also worked as a Scientist at EMBL and Sapienza Università di Roma. Previously, Marco had an internship at the DKFZ German Cancer Research Center focusing on computational epigenomics. Prior to their scientific roles, Marco worked in sales and customer service at Pfitzenmeier. Marco holds a Bachelor's degree in Molecular biotechnology from Heidelberg University and is currently pursuing a Master's degree in the same field.
National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.